➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Mallinckrodt
Medtronic
Colorcon
Merck

Last Updated: August 4, 2021

DrugPatentWatch Database Preview

Patent: 5,578,461

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 5,578,461
Title: Gene manipulation and expression using genomic elements
Abstract:Expression of mammalian target genes is achieved by employing chromosomal target DNA, either native primary cells or YACs in a yeast host, where the YACs include a fragment of a mammalian chromosome, the fragment comprising the target gene. Employing homologous recombination, an amplifiable gene is integrated into the mammalian fragment at a site to allow for amplification. In the same step, or one or more steps, as desired, the mammalian gene and/or the transcriptional system may be modified by in vivo mutagenesis. The resulting construct from homologous recombination may then be transformed into a mammalian expression host and integrated into the host genome, either randomly or by homologous recombination. The amplifiable gene may then be amplified by an appropriate agent providing for multiple copies of the target gene and the expression host grown to provide for high yields of the desired wild-type or modified protein.
Inventor(s): Sherwin; Stephen (San Francisco, CA), Klapholz; Sue (Stanford, CA), Skoultchi; Arthur (Larchmont, NY)
Assignee: Cell Genesys, Inc. (Foster City, CA)
Application Number:08/102,567
Patent Claims:see list of patent claims

Details for Patent 5,578,461

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ⤷  Free Forever Trial Cell Genesys, Inc. (Foster City, CA) 2013-11-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ⤷  Free Forever Trial Cell Genesys, Inc. (Foster City, CA) 2013-11-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ⤷  Free Forever Trial Cell Genesys, Inc. (Foster City, CA) 2013-11-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 5,578,461

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 9106666 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 9106667 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 9219255 ⤷  Free Forever Trial
United States of America 2004265860 ⤷  Free Forever Trial
United States of America 5981214 ⤷  Free Forever Trial
United States of America 6015708 ⤷  Free Forever Trial
Singapore 122763 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Colorcon
Merck
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.